Protagonist Therapeutics, Inc. Stock price

Equities

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
28.93 USD +1.58% Intraday chart for Protagonist Therapeutics, Inc. +2.05% +26.17%
Sales 2024 * 208M Sales 2025 * 120M Capitalization 1.69B
Net income 2024 * 24M Net income 2025 * -6M EV / Sales 2024 * 6.26 x
Net cash position 2024 * 388M Net cash position 2025 * 637M EV / Sales 2025 * 8.75 x
P/E ratio 2024 *
79.7 x
P/E ratio 2025 *
-35.7 x
Employees 112
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.48%
More Fundamentals * Assessed data
Dynamic Chart
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda CI
Protagonist Therapeutics' Potential Plaque Psoriasis Drug Shows High Skin Clearance Rates in Phase 2B Study MT
Protagonist Therapeutics, Inc. Announces Late-Breaking Presentation At the American Academy of Dermatology 2024 Annual Meeting with Positive Results from the Phase 2B Frontier 2 Long-Term Extension Study Evaluating JNJ-2113, the First and Only Investigational Targeted Oral Peptide Designed to Block the IL-23 Receptor, for Adult Patients with Moderate-To-Severe Plaque Psoriasis CI
Protagonist Therapeutics Insider Sold Shares Worth $948,600, According to a Recent SEC Filing MT
Protagonist Therapeutics Insider Sold Shares Worth $406,637, According to a Recent SEC Filing MT
Protagonist Therapeutics Insider Sold Shares Worth $764,365, According to a Recent SEC Filing MT
JPMorgan Adjusts Price Target on Protagonist Therapeutics to $37 From $34, Maintains Overweight Rating MT
Protagonist Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Protagonist Therapeutics Shares Rise 5.6% on Licensing Deal With Takeda DJ
Transcript : Protagonist Therapeutics, Inc. - Special Call
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset CI
Transcript : Protagonist Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:45 AM
Protagonist Therapeutics Insider Sold Shares Worth $1,506,000, According to a Recent SEC Filing MT
Protagonist Therapeutics Earns $10 Million Milestone Payment in Ulcerative Colitis Trial MT
More news

Latest transcript on Protagonist Therapeutics, Inc.

1 day+1.58%
1 week+2.05%
Current month-4.77%
1 month-4.93%
3 months+25.08%
6 months+68.88%
Current year+26.17%
More quotes
1 week
27.59
Extreme 27.585
29.27
1 month
27.59
Extreme 27.585
33.34
Current year
21.43
Extreme 21.43
33.34
1 year
13.72
Extreme 13.72
33.34
3 years
6.91
Extreme 6.91
50.54
5 years
4.47
Extreme 4.47
50.54
10 years
4.47
Extreme 4.47
50.54
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 08-11-30
Director of Finance/CFO 50 22-04-17
Chief Tech/Sci/R&D Officer - 17-06-30
Members of the board TitleAgeSince
Director/Board Member 74 17-06-07
Chairman 69 09-01-31
Director/Board Member 61 23-10-25
More insiders
Date Price Change Volume
24-03-28 28.93 +1.58% 653,366
24-03-27 28.48 +1.71% 359,436
24-03-26 28 +0.39% 307,470
24-03-25 27.89 -0.50% 247,394
24-03-22 28.03 -1.13% 376,485

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
28.93 USD
Average target price
43 USD
Spread / Average Target
+48.63%
Consensus
  1. Stock
  2. Equities
  3. Stock Protagonist Therapeutics, Inc. - Nasdaq